Jenburkt is making favipiravir (brand name Favivent) at a pharmaceutical plant which is compliant with USFDA
(US Food and Drug Administration) in the state of Telangana. The medication will be available in the form of one strip of 10 tablets.
Earlier this year, the Drug Controller General of India approved the use of favipiravir – an antiviral drug developed in Japan and commonly used for treating influenza – for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is a broad spectrum anti-viral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication.
Ashish U Bhuta, CMD of Jenurkt, said, “With the rising number of cases, our country’s medical infrastructure and front-line warriors are under tremendous pressure at the moment. We hope the easy accessibility and affordable price point of an effective treatment such as Favivent will offer our citizens a timely, much-needed therapeutic solution.”